Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

A Framework for MRI Characterization of Intracranial Metastatic Disease.

Radiology. Imaging cancer·2026
Same author

Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

European journal of cancer (Oxford, England : 1990)·2025
Same author

CP-GEP identifies high-risk T1a melanoma patients beyond established adverse features.

Journal of the American Academy of Dermatology·2025
Same author

Next-Generation Oncolytic Viruses to Overcome Resistance to Anti-PD-1 Therapy in Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological Heterogeneity.

Molecular imaging and biology·2025

Related Experiment Video

Updated: Apr 14, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K

Radiotherapy complements immune checkpoint blockade.

Shin Foong Ngiow1, Grant A McArthur2, Mark J Smyth1

  • 1Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia.

Cancer Cell
|April 16, 2015
PubMed
Summary

Anti-PD-L1 therapy overcomes adaptive immune resistance to enhance anti-tumor responses. Combining radiation with dual immune checkpoint blockade, like anti-CTLA-4, shows superior efficacy through distinct immune mechanisms in cancer.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Related Experiment Videos

Last Updated: Apr 14, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Area of Science:

  • Immunology
  • Oncology
  • Radiation Therapy

Background:

  • Adaptive immune resistance hinders effective anti-tumor immune responses.
  • Immune checkpoint inhibitors (ICIs) are crucial in cancer therapy.
  • Combining therapies can overcome resistance mechanisms.

Purpose of the Study:

  • To investigate the efficacy of anti-PD-L1 in overcoming adaptive immune resistance.
  • To evaluate the combined effect of localized radiation and anti-CTLA-4 therapy with anti-PD-L1.
  • To elucidate the immune mechanisms underlying the superior activity of combined treatments.

Main Methods:

  • Utilized localized radiation therapy.
  • Administered dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-L1).
  • Analyzed non-redundant immune mechanisms in cancer models.

Main Results:

  • Anti-PD-L1 therapy effectively combats adaptive immune resistance.
  • The combination of radiation and dual immune checkpoint blockade demonstrated superior anti-tumor activity.
  • Non-redundant immune mechanisms mediate the enhanced efficacy of the combined treatment.

Conclusions:

  • Combining localized radiation with dual immune checkpoint blockade (anti-CTLA-4 and anti-PD-L1) is a promising strategy for cancer treatment.
  • Targeting adaptive immune resistance is critical for improving immunotherapy outcomes.
  • Distinct immune pathways contribute to the synergistic effects of combined cancer therapies.